A Phase 3 interventional study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) and Macular Laser Photocoagulation in Diabetic Macular Edema, sponsored by Regeneron Pharmaceuticals. Completed at 51 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-30.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing aflibercept in Diabetic Retinopathy — 2 open to participants now, 4 under way, none of them phase 3. aflibercept · Diabetic Retinopathy.
Among the 21 studies testing aflibercept in Diabetic Retinopathy, this one has the largest enrollment, is the only one that started in 2011, is one of 3 in phase 3, and was the 1st registered.
779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.
Browse Diabetic Retinopathy studies →2 of the 21 studies testing aflibercept in Diabetic Retinopathy are open now, in 2 countries. Recruiting first, the newest first:
Retina Consultants of Orange County · Sites in United States
Ages 21+
Ahmad Zeeshan Jamil · Sites in Pakistan
Ages 40+
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 5 · Phase 4 8
First in 2011; this study’s year is marked. 1 started in 2011.
This study's enrollment of 466 is above the median of 80 across 482 interventional studies indexed under Diabetic Retinopathy.
Median enrollment 38 across the 21 interventional studies. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 21 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 6 studies filed under Diabetic Retinopathy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing aflibercept in Diabetic Retinopathy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) on the best corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in patients with diabetic macular edema (DME) with central involvement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following is an abbreviated list of inclusion criteria:
Exclusion Criteria:
The following is an abbreviated list of exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received macular laser treatment at baseline and as-needed at visits at which laser re-treatment criteria were met, but no more frequently than every 12 weeks.
Procedure: Macular Laser Photocoagulation
Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks.
Drug: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks for 5 visits followed by injections every 8 weeks.
Drug: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
Laser therapy
Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)
Visual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye were included; a higher score represents better functioning.
Time frame: Baseline and Week 52
Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF
Time frame: Baseline and Week 52
Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF
Time frame: Baseline and Week 52
Percentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF
Baseline ETDRS DRSS: None (level 10); Mild to moderate nonproliferative DR (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)
Time frame: Baseline and Week 52
Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF
Time frame: Baseline and Week 52
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.
Time frame: Baseline and Week 52
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.
Time frame: Baseline and Week 52
Participants with diabetic macular edema (DME) secondary to diabetes mellitus involving the center of the macula in the study eye could participate in the study.
| Milestone | Macular Laser Photocoagulation Treatment (Control) | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 |
|---|---|---|---|
| Started | 156 | 156 | 154 |
| Participants received treatment | 154 | 155 | 152 |
| Completed week 52 | 145 | 146 | 144 |
| Completed week 100 | 133 | 125 | 127 |
| Completed | 133 | 125 | 127 |
| Not completed | 23 | 31 | 27 |
| Withdrew: Adverse event | 5 | 4 | 4 |
| Withdrew: Death | 3 | 7 | 5 |
| Withdrew: Withdrawal by subject | 9 | 11 | 11 |
| Withdrew: Lost to follow-up | 2 | 4 | 5 |
| Withdrew: Other | 4 | 5 | 2 |
Visual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye were included; a higher score represents better functioning.
| letters correctly read | Control | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 |
|---|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF) | .10 ± 1.03 | 12.3 ± .76 | 10.6 ± .69 |
| percentage of participants | Control | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 |
|---|---|---|---|
| Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF | 30 | 100 | 88 |
| percentage of participants | Control | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 |
|---|---|---|---|
| Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF | 12 | 64 | 47 |
Baseline ETDRS DRSS: None (level 10); Mild to moderate nonproliferative DR (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)
| percentage of participants | Control | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 |
|---|---|---|---|
| Percentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF | 22 | 52 | 44 |
| microns | Control | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 |
|---|---|---|---|
| Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF | -73.3 ± 12.09 | -184.1 ± 6.57 | -186.8 ± 6.90 |
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.
| scores on a scale | Control | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 |
|---|---|---|---|
| Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF | 3.7 ± 1.55 | 8.9 ± 1.58 | 8.1 ± 1.44 |
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.
| scores on a scale | Control | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 |
|---|---|---|---|
| Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF | 4.9 ± 1.44 | 7.7 ± 1.57 | 6.5 ± 1.48 |
Collected over From the first study drug injection until 30 days after the last study drug injection at the latest from week 0 to week 100; From the first study drug injection until 30 days after the last study drug injection at the latest from week 0 to week 148.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control (Week 0 to Week 100) | — | 67/154 (43.5%) | 91/154 (59.1%) |
| IAI;EYLEA®;BAY86-5321 2Q4 (Week 0 to Week 100) | — | 67/155 (43.2%) | 90/155 (58.1%) |
| IAI;EYLEA®;BAY86-5321) 2Q8 (Week 0 to Week 100) | — | 56/152 (36.8%) | 76/152 (50%) |
| Control (Week 0 to Week 148) | — | 84/154 (54.5%) | 134/154 (87%) |
| IAI;EYLEA®;BAY86-5321 2Q4 (Week 0 to Week 148) | — | 85/155 (54.8%) | 137/155 (88.4%) |
| IAI;EYLEA®;BAY86-5321) 2Q8 (Week 0 to Week 148) | — | 75/152 (49.3%) | 136/152 (89.5%) |
| Event | Control (Week 0 to Week 100) | IAI;EYLEA®;BAY86-5321 2Q4 (Week 0 to Week 100) | IAI;EYLEA®;BAY86-5321) 2Q8 (Week 0 to Week 100) | Control (Week 0 to Week 148) | IAI;EYLEA®;BAY86-5321 2Q4 (Week 0 to Week 148) | IAI;EYLEA®;BAY86-5321) 2Q8 (Week 0 to Week 148) |
|---|---|---|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 5/154 | 9/155 | 5/152 | 6/154 | 11/155 | 6/152 |
| AnaemiaBlood and lymphatic system disorders | 1/154 | 9/155 | 5/152 | 2/154 | 10/155 | 6/152 |
| Renal failure acuteRenal and urinary disorders | 7/154 | 6/155 | 6/152 | 9/154 | 10/155 | 8/152 |
| Vitreous haemorrhageEye disorders | 2/154 | 7/155 | 2/152 | 3/154 | 9/155 | 4/152 |
| Vitreous haemorrhageEye disorders | 0/154 | 0/155 | 0/152 | 3/154 | 9/155 | 4/152 |
| CellulitisInfections and infestations | 4/154 | 7/155 | 8/152 | 5/154 | 9/155 | 8/152 |
| OsteomyelitisInfections and infestations | 3/154 | 5/155 | 2/152 | 5/154 | 7/155 | 3/152 |
| HyperkalaemiaMetabolism and nutrition disorders | 4/154 | 3/155 | 1/152 | 6/154 | 4/155 | 1/152 |
| PneumoniaInfections and infestations | 4/154 | 4/155 | 3/152 | 4/154 | 6/155 | 4/152 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/154 | 5/155 | 0/152 | 1/154 | 6/155 | 0/152 |
| Event | Control (Week 0 to Week 100) | IAI;EYLEA®;BAY86-5321 2Q4 (Week 0 to Week 100) | IAI;EYLEA®;BAY86-5321) 2Q8 (Week 0 to Week 100) | Control (Week 0 to Week 148) | IAI;EYLEA®;BAY86-5321 2Q4 (Week 0 to Week 148) | IAI;EYLEA®;BAY86-5321) 2Q8 (Week 0 to Week 148) |
|---|---|---|---|---|---|---|
| Conjunctival haemorrhageEye disorders | 53/154 | 63/155 | 48/152 | 55/154 | 63/155 | 50/152 |
| HypertensionVascular disorders | 49/154 | 41/155 | 42/152 | 56/154 | 51/155 | 49/152 |
| Conjunctival haemorrhageEye disorders | 29/154 | 30/155 | 27/152 | 31/154 | 35/155 | 29/152 |
| Urinary tract infectionInfections and infestations | 14/154 | 17/155 | 26/152 | 20/154 | 30/155 | 32/152 |
| Diabetic retinal oedemaEye disorders | 19/154 | 22/155 | 18/152 | 26/154 | 29/155 | 23/152 |
| Diabetes mellitusMetabolism and nutrition disorders | 20/154 | 13/155 | 19/152 | 28/154 | 23/155 | 25/152 |
| CataractEye disorders | 16/154 | 21/155 | 13/152 | 24/154 | 28/155 | 21/152 |
| AnaemiaBlood and lymphatic system disorders | 12/154 | 20/155 | 12/152 | 15/154 | 27/155 | 20/152 |
| Eye painEye disorders | 20/154 | 23/155 | 21/152 | 23/154 | 23/155 | 26/152 |
| Vitreous detachmentEye disorders | 15/154 | 14/155 | 22/152 | 20/154 | 20/155 | 25/152 |
Baseline population analyzed using the SAF
| Age, Continuous(years) | Control | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 | Total |
|---|---|---|---|---|
| Mean | 61.7 ± 8.65 | 62 ± 11.16 | 63.1 ± 9.36 | 62.2 ± 9.7 |
| Sex: Female, Male(Participants) | Control | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 | Total |
|---|---|---|---|---|
| Female | 69 | 68 | 73 | 210 |
| Male | 85 | 87 | 79 | 251 |
The record gives a start of May 2011, a primary completion of Jan 2013 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 2 years 3 months after primary completion. A results delay was requested in Feb 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept